共 50 条
- [22] Molecular mechanism in urothelial carcinoma with FGFR3 mutation. [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16548 - E16548
- [25] Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation [J]. FRONTIERS IN ONCOLOGY, 2021, 11
- [27] Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma [J]. MEDICINA-LITHUANIA, 2024, 60 (04):